Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting gBRCA1/2 mutations?
@article{GS134987,
author = {Pierre Foidart and Guy Jerusalem},
title = {Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting gBRCA1/2 mutations?},
journal = {Gland Surgery},
volume = {14},
number = {2},
year = {2025},
keywords = {},
abstract = {},
issn = {2227-8575}, url = {https://gs.amegroups.org/article/view/134987}
}